Nelson Côrtes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nelson Côrtes has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aline Aparecida de Lima Lira
University of São Paulo
4 shared publications - Gustavo Cabral-Miranda
University of São Paulo
4 shared publications - Lorena Carvalho de Souza Chaves
Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University Atlanta Georgia USA
4 shared publications - Niels Olsen Saraiva Câmara
Federal University of São Paulo
4 shared publications - Otavio Cabral-Marques
Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil
4 shared publications - Wasim Aluísio Prates-Syed
Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), Clinical Hospital, Faculty of Medicine, University of São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 44, 05403-900, São Paulo, SP, Brazil
4 shared publications
Latest Publications
- Open Access
- 7 August 2024
- Published by Springer Nature in Research Square
COVID-19 vaccination atlas: an integrative systems vaccinology approach
The COVID-19 vaccinations have played a significant role in controlling the pandemic. To elucidate their impact on the immune system, a COVID-19 vaccination atlas was developed through an integrative systems vaccinology approach. The atlas includes both healthy individuals and those infected with or without prior vaccination, and covers the administration of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®, Spikevax®, and Comirnaty®. Critical markers were identified to discriminate the different types of vaccines and infection, in which infection was associated with GATA3, ZNF3, KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1, LGALS3, and STAT5B. Additionally, the immunological signatures of heterologous vaccination and infection were described, and it was also shown how a full vaccination regimen markedly limited the shift of immune responses during natural infection, thereby constraining disease progression. Finally, the common transcripts shared across COVID-19 vaccines and vaccines against other pathogens were described.
- 7 August 2024
- Published by Springer Nature in Research Square
Open AccessCOVID-19 vaccination atlas: an integrative systems vaccinology approach
The COVID-19 vaccinations have played a significant role in controlling the pandemic. To elucidate their impact on the immune system, a COVID-19 vaccination atlas was developed through an integrative systems vaccinology approach. The atlas includes both healthy individuals and those infected with or without prior vaccination, and covers the administration of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®, Spikevax®, and Comirnaty®. Critical markers were identified to discriminate the different types of vaccines and infection, in which infection was associated with GATA3, ZNF3, KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1, LGALS3, and STAT5B. Additionally, the immunological signatures of heterologous vaccination and infection were described, and it was also shown how a full vaccination regimen markedly limited the shift of immune responses during natural infection, thereby constraining disease progression. Finally, the common transcripts shared across COVID-19 vaccines and vaccines against other pathogens were described.
- Open Access
COVID-19 vaccination atlas: an integrative systems vaccinology approach
The COVID-19 vaccinations have played a significant role in controlling the pandemic. To elucidate their impact on the immune system, a COVID-19 vaccination atlas was developed through an integrative systems vaccinology approach. The atlas includes both healthy individuals and those infected with or without prior vaccination, and covers the administration of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®, Spikevax®, and Comirnaty®. Critical markers were identified to discriminate the different types of vaccines and infection, in which infection was associated with GATA3, ZNF3, KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1, LGALS3, and STAT5B. Additionally, the immunological signatures of heterologous vaccination and infection were described, and it was also shown how a full vaccination regimen markedly limited the shift of immune responses during natural infection, thereby constraining disease progression. Finally, the common transcripts shared across COVID-19 vaccines and vaccines against other pathogens were described.
Open AccessCOVID-19 vaccination atlas: an integrative systems vaccinology approach
The COVID-19 vaccinations have played a significant role in controlling the pandemic. To elucidate their impact on the immune system, a COVID-19 vaccination atlas was developed through an integrative systems vaccinology approach. The atlas includes both healthy individuals and those infected with or without prior vaccination, and covers the administration of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®, Spikevax®, and Comirnaty®. Critical markers were identified to discriminate the different types of vaccines and infection, in which infection was associated with GATA3, ZNF3, KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1, LGALS3, and STAT5B. Additionally, the immunological signatures of heterologous vaccination and infection were described, and it was also shown how a full vaccination regimen markedly limited the shift of immune responses during natural infection, thereby constraining disease progression. Finally, the common transcripts shared across COVID-19 vaccines and vaccines against other pathogens were described.
- Open Access
Vaccines against Emerging and Neglected Infectious Diseases: An Overview
Neglected Tropical Diseases (NTDs) are a group of diseases that are highly prevalent in tropical and subtropical regions, and closely associated with poverty and marginalized populations. Infectious diseases affect over 1.6 billion people annually, and vaccines are the best prophylactic tool against them. Along with NTDs, emerging and reemerging infectious diseases also threaten global public health, as they can unpredictably result in pandemics. The recent advances in vaccinology allowed the development and licensing of new vaccine platforms that can target and prevent these diseases. In this work, we discuss the advances in vaccinology and some of the difficulties found in the vaccine development pipeline for selected NTDs and emerging and reemerging infectious diseases, including HIV, Dengue, Ebola, Chagas disease, malaria, leishmaniasis, zika, and chikungunya.
Open AccessVaccines against Emerging and Neglected Infectious Diseases: An Overview
Neglected Tropical Diseases (NTDs) are a group of diseases that are highly prevalent in tropical and subtropical regions, and closely associated with poverty and marginalized populations. Infectious diseases affect over 1.6 billion people annually, and vaccines are the best prophylactic tool against them. Along with NTDs, emerging and reemerging infectious diseases also threaten global public health, as they can unpredictably result in pandemics. The recent advances in vaccinology allowed the development and licensing of new vaccine platforms that can target and prevent these diseases. In this work, we discuss the advances in vaccinology and some of the difficulties found in the vaccine development pipeline for selected NTDs and emerging and reemerging infectious diseases, including HIV, Dengue, Ebola, Chagas disease, malaria, leishmaniasis, zika, and chikungunya.
- Open Access
VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Virus-like particles (VLPs) are a versatile, safe, and highly immunogenic vaccine platform. Recently, there are developmental vaccines targeting SARS-CoV-2, the causative agent of COVID-19. The COVID-19 pandemic affected humanity worldwide, bringing out incomputable human and financial losses. The race for better, more efficacious vaccines is happening almost simultaneously as the virus increasingly produces variants of concern (VOCs). The VOCs Alpha, Beta, Gamma, and Delta share common mutations mainly in the spike receptor-binding domain (RBD), demonstrating convergent evolution, associated with increased transmissibility and immune evasion. Thus, the identification and understanding of these mutations is crucial for the production of new, optimized vaccines. The use of a very flexible vaccine platform in COVID-19 vaccine development is an important feature that cannot be ignored. Incorporating the spike protein and its variations into VLP vaccines is a desirable strategy as the morphology and size of VLPs allows for better presentation of several different antigens. Furthermore, VLPs elicit robust humoral and cellular immune responses, which are safe, and have been studied not only against SARS-CoV-2 but against other coronaviruses as well. Here, we describe the recent advances and improvements in vaccine development using VLP technology.
Open AccessVLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Virus-like particles (VLPs) are a versatile, safe, and highly immunogenic vaccine platform. Recently, there are developmental vaccines targeting SARS-CoV-2, the causative agent of COVID-19. The COVID-19 pandemic affected humanity worldwide, bringing out incomputable human and financial losses. The race for better, more efficacious vaccines is happening almost simultaneously as the virus increasingly produces variants of concern (VOCs). The VOCs Alpha, Beta, Gamma, and Delta share common mutations mainly in the spike receptor-binding domain (RBD), demonstrating convergent evolution, associated with increased transmissibility and immune evasion. Thus, the identification and understanding of these mutations is crucial for the production of new, optimized vaccines. The use of a very flexible vaccine platform in COVID-19 vaccine development is an important feature that cannot be ignored. Incorporating the spike protein and its variations into VLP vaccines is a desirable strategy as the morphology and size of VLPs allows for better presentation of several different antigens. Furthermore, VLPs elicit robust humoral and cellular immune responses, which are safe, and have been studied not only against SARS-CoV-2 but against other coronaviruses as well. Here, we describe the recent advances and improvements in vaccine development using VLP technology.